In the last few years, immunotherapy has transformed the way we treat solid tumors,
including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable …

Neutrophils are expanded and abundant in cancer-bearing hosts. Under the influence of
CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced …

Background: Drug-induced colitis is a known complication of therapies that alter the immune
balance, damage the intestinal barrier or disturb intestinal microbiota. Immune checkpoint …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Importance High body mass index (BMI) is independently associated with overall survival
benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether …

Barrier tissues are populated by functionally plastic CD4+ resident memory T (TRM) cells.
Whether the barrier epithelium regulates CD4+ TRM cell locations, plasticity and activities …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy …

Abstract Background Immune‐checkpoint inhibitors (ICIs) are now standard of care for
advanced non‐small cell lung cancer (NSCLC). Unfortunately, many patients experience …

Purpose: Tumor mutational burden (TMB) has emerged as a potential predictive biomarker
for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown …

Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are
associated with unique adverse events, including potentially life-threatening pneumonitis …